| Product Code: ETC7745530 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Overview |
3.1 Japan Country Macro Economic Indicators |
3.2 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, 2021 & 2031F |
3.3 Japan Pharmacogenetics Testing in Psychiatry/Depression Market - Industry Life Cycle |
3.4 Japan Pharmacogenetics Testing in Psychiatry/Depression Market - Porter's Five Forces |
3.5 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Test Type, 2021 & 2031F |
3.7 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Gene Type, 2021 & 2031F |
3.8 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Patient Type, 2021 & 2031F |
3.9 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Product, 2021 & 2031F |
3.10 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.11 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness among healthcare providers about the benefits of pharmacogenetics testing in psychiatry/depression |
4.2.2 Growing demand for personalized medicine in Japan |
4.2.3 Rise in mental health disorders leading to a higher need for effective treatment options |
4.3 Market Restraints |
4.3.1 High costs associated with pharmacogenetics testing procedures |
4.3.2 Limited reimbursement policies for pharmacogenetics testing in psychiatry/depression |
4.3.3 Regulatory challenges and uncertainties surrounding genetic testing in Japan |
5 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Trends |
6 Japan Pharmacogenetics Testing in Psychiatry/Depression Market, By Types |
6.1 Japan Pharmacogenetics Testing in Psychiatry/Depression Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Anxiety, 2021- 2031F |
6.1.4 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Mood Disorders, 2021- 2031F |
6.1.5 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Depression, 2021- 2031F |
6.1.6 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Bipolar Disorders, 2021- 2031F |
6.1.7 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Psychotic Disorders, 2021- 2031F |
6.1.8 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Eating Disorders, 2021- 2031F |
6.2 Japan Pharmacogenetics Testing in Psychiatry/Depression Market, By Test Type |
6.2.1 Overview and Analysis |
6.2.2 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Whole Genome Sequencing, 2021- 2031F |
6.2.3 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Chromosomal Array-Based Tests, 2021- 2031F |
6.3 Japan Pharmacogenetics Testing in Psychiatry/Depression Market, By Gene Type |
6.3.1 Overview and Analysis |
6.3.2 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By CYP2C19, 2021- 2031F |
6.3.3 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By CYP2C9 AND VKORC1, 2021- 2031F |
6.3.4 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By CYP2D6, 2021- 2031F |
6.3.5 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By HLA-B, 2021- 2031F |
6.3.6 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By HTR2A/C, 2021- 2031F |
6.3.7 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By HLA-A, 2021- 2031F |
6.4 Japan Pharmacogenetics Testing in Psychiatry/Depression Market, By Patient Type |
6.4.1 Overview and Analysis |
6.4.2 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Child, 2021- 2031F |
6.4.3 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Adult, 2021- 2031F |
6.4.4 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Geriatric, 2021- 2031F |
6.5 Japan Pharmacogenetics Testing in Psychiatry/Depression Market, By Product |
6.5.1 Overview and Analysis |
6.5.2 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Instruments, 2021- 2031F |
6.5.3 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Consumables, 2021- 2031F |
6.5.4 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Software & Services, 2021- 2031F |
6.6 Japan Pharmacogenetics Testing in Psychiatry/Depression Market, By End User |
6.6.1 Overview and Analysis |
6.6.2 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Hospitals & Clinics, 2021- 2031F |
6.6.3 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Dignostics Laboratories, 2021- 2031F |
6.6.4 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Academic And Research Institutes, 2021- 2031F |
6.6.5 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Others, 2021- 2031F |
6.7 Japan Pharmacogenetics Testing in Psychiatry/Depression Market, By Distribution Channel |
6.7.1 Overview and Analysis |
6.7.2 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Direct Tender, 2021- 2031F |
6.7.3 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Third-Party Distribution, 2021- 2031F |
6.7.4 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Others, 2021- 2031F |
6.7.5 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Others, 2021- 2031F |
7 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Import-Export Trade Statistics |
7.1 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Export to Major Countries |
7.2 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Imports from Major Countries |
8 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Key Performance Indicators |
8.1 Adoption rate of pharmacogenetics testing in psychiatric/depression treatments |
8.2 Number of healthcare facilities offering pharmacogenetics testing services |
8.3 Patient satisfaction and outcomes improvement post pharmacogenetics testing |
9 Japan Pharmacogenetics Testing in Psychiatry/Depression Market - Opportunity Assessment |
9.1 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Test Type, 2021 & 2031F |
9.3 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Gene Type, 2021 & 2031F |
9.4 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Patient Type, 2021 & 2031F |
9.5 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Product, 2021 & 2031F |
9.6 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By End User, 2021 & 2031F |
9.7 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Japan Pharmacogenetics Testing in Psychiatry/Depression Market - Competitive Landscape |
10.1 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Revenue Share, By Companies, 2024 |
10.2 Japan Pharmacogenetics Testing in Psychiatry/Depression Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here